Scinai Immunotherapeutics Ltd. (SCNI) stock
Close on Nov 13, 2026Market cap $1.39MP/E –Yield –
Scinai Immunotherapeutics Ltd. grew revenue 99.2% to $1.31M over fiscal 2025. Free cash flow was -$6.06M. At the latest close the market valued the company at $1.39M.
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Jun 30, 2026
Valuation
- Market cap
- $1.39M
- P/E ratio
- –
- Price to sales
- 1.06
- Price to book
- 0.12
- Dividend yield
- –
- Free cash flow yield
- -436.46%
Fundamentals
- Revenue
- $1.31M
- Net income
- -$8.31M
- Free cash flow
- -$6.06M
Trading
- Previous close
- $0.44
- Open
- $0.45
- Day's range
- $0.39 – $0.45
- Volume
- 94,986
- Average volume (20 days)
- 97,165
- Beta (5 years)
- 1.48
- 52-week range
- $0.39 – $13.00
- RSI (14 days)
- 25.2
- Volatility (1 year)
- 136.0%
- Relative volume
- 0.06×
- WACC
- 12.5%
Market cap history
Month-end market cap since 2016, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.
| Period | SCNI | S&P 500 | Difference | SCNI per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -67.5% | -3.0% | −64.4 pts | ||
| 3 months | -83.3% | -2.8% | −80.6 pts | ||
| Year to date | -94.4% | +11.5% | −105.9 pts | ||
| 1 year | -96.0% | +13.5% | −109.5 pts | ||
| 3 years | -99.3% | +77.7% | −177.0 pts | -81.2% | +21.1% |
| 5 years | -100.0% | +72.6% | −172.6 pts | -82.1% | +11.5% |
| 10 years | -100.0% | +308.2% | −408.1 pts | -59.7% | +15.1% |
Eleven years at a glance
Fiscal years 2015 to 2025, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Scinai Immunotherapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
About Scinai Immunotherapeutics
Biological Products, (No Diagnostic Substances)
Scinai Immunotherapeutics Ltd. is an Israeli biopharmaceutical company that operates two distinct business segments: a contract development and manufacturing organization (CDMO) and an in-house research and development unit. The CDMO business unit provides biopharmaceutical development and manufacturing services to external clients. Meanwhile, the R&D segment focuses on advancing biological therapeutics for inflammation and immunology conditions, primarily through a pipeline of nanosized VHH antibody fragments. Its therapeutic development efforts include targeting Interleukin-17 for autoimmune diseases such as plaque psoriasis and psoriatic arthritis, as well as an optioned monoclonal antibody candidate targeting soluble Fas ligand.
Company profile, executives and historyScinai Immunotherapeutics stock: common questions
What is Scinai Immunotherapeutics's stock price?
SCNI closed at $0.40 on Nov 13, 2026, down 9.50% on the day. Over the past 52 weeks it traded between $0.39 and $13.00.
What is Scinai Immunotherapeutics's market cap?
Scinai Immunotherapeutics was worth $1.39M at the close on Nov 13, 2026: the share price times the diluted shares outstanding.
How much revenue does Scinai Immunotherapeutics make?
Scinai Immunotherapeutics reported revenue of $1.31M for fiscal 2025, up 99.2% from a year earlier.
Does Scinai Immunotherapeutics pay a dividend?
No. Scinai Immunotherapeutics has not paid a cash dividend over the last twelve months.
How has SCNI stock performed over the past year?
Including dividends, SCNI returned -96.0% over the past year, against +13.5% for the S&P 500.
Who are Scinai Immunotherapeutics's competitors?
Companies most similar to Scinai Immunotherapeutics by business, industry and size include SABS, PLUR, IMA, INBX, OTLK.
See a number that looks wrong?